Competitor accuses 23andMe of ‘false negatives’ in cancer-gene testing
When 23andMe received government permission in 2017 to sell health-related genetic testing, it came with several conditions, including that the company tell customers that its brand of testing can miss disease-causing variants. Now, in a study presented on Thursday at the annual meeting of the American Society of Human Genetics, a competitor has analyzed the likelihood of such “false negatives,” concluding that in some ethnic groups the chance that 23andMe’s tests will miss a cancer-causing DNA variant is 100%.
23andMe pushed back hard on that conclusion from DNA testing company Invitae. “It is patently wrong to state that 23andMe delivers ‘false negatives’ for variants that it does not test nor claim to test for,” said a company spokesman. “This is a false and misleading characterization of 23andMe’s test.”
Read Original Article: Competitor accuses 23andMe of ‘false negatives’ in cancer-gene testing »
